List of Excipients in Branded Drug LIDODERM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
STAT RX USA LLC	LIDODERM	lidocaine	16590-141	CARBOXYMETHYLCELLULOSE SODIUM
STAT RX USA LLC	LIDODERM	lidocaine	16590-141	EDETATE DISODIUM
STAT RX USA LLC	LIDODERM	lidocaine	16590-141	GELATIN
STAT RX USA LLC	LIDODERM	lidocaine	16590-141	GLYCERIN

Lidoderm Excipient Strategy and Commercial Opportunities for Lidocaine 5% Patches

Last updated: September 3, 2026

Lidoderm is a lidocaine 5% topical patch whose commercial value depends more on adhesive engineering, skin tolerability, drug release, and manufacturing control than on the active ingredient. The core opportunity is a lower-cost generic or differentiated 5% lidocaine patch using a reliable adhesive matrix, controlled lidocaine crystallization, improved liner removal, and better wear performance.

What is Lidoderm and how does its formulation work?

Lidoderm is a prescription lidocaine 5% patch approved by the FDA for the relief of pain associated with post-herpetic neuralgia. Each 10 cm by 14 cm patch contains 700 mg of lidocaine. The labeled dosing regimen is up to three patches applied simultaneously for a maximum of 12 hours within a 24-hour period.[1]

The product is a drug-in-adhesive matrix patch. Lidocaine is incorporated directly into the adhesive layer rather than being held in a separate drug reservoir. This design reduces structural complexity but places greater technical demands on excipient selection.

Lidoderm dosage-form architecture

Component	Function
Lidocaine	Local anesthetic active ingredient
Gelatin	Adhesive or matrix structuring agent
Kaolin	Mineral filler and rheology modifier
Sodium carboxymethylcellulose	Water-management and viscosity control
Propylene glycol	Solvent and humectant
Polyacrylic acid	Adhesive, thickening, and matrix-forming polymer
Liquid paraffin	Emollient and hydrophobic phase modifier
Purified water	Processing solvent and matrix component
Polyester backing	Prevents drug loss through the rear surface
Release liner	Protects the adhesive before application

The labeled inactive ingredients are central to performance. A formulation that matches the lidocaine concentration but fails on tack, peel, cohesion, release, or skin compatibility can be commercially unacceptable.

What excipients are used in Lidoderm?

The Lidoderm label identifies gelatin, kaolin, sodium carboxymethylcellulose, propylene glycol, polyacrylic acid, liquid paraffin, and purified water as inactive ingredients.[1]

Gelatin and polyacrylic acid

Gelatin and polyacrylic acid contribute to the cohesive structure of the adhesive layer. Their interaction affects:

• Wet and dry tack
• Peel strength
• Cohesive failure
• Cold-flow resistance
• Patch edge lift
• Drug diffusion
• Residual adhesive after removal

Gelatin introduces a biological raw material into the supply chain. Its source, grade, microbiological quality, residual processing agents, and regulatory documentation require control. A generic developer can reduce supply risk by replacing gelatin with a synthetic or semisynthetic polymer system, but that change may alter adhesive performance and require comparative adhesion and irritation studies.

Polyacrylic acid can improve viscosity and matrix integrity. Its neutralization state and molecular weight influence the patch’s water sensitivity, pH, swelling, and lidocaine release.

Propylene glycol

Propylene glycol can dissolve or plasticize the formulation and can increase molecular mobility within the matrix. It may also affect lidocaine partitioning into the skin.

Its commercial advantages include broad pharmaceutical use, availability, and relatively low cost. The risks are concentration-dependent skin irritation, changes in adhesive tack, and increased migration of lidocaine or other formulation components.

Kaolin

Kaolin acts as a mineral filler and rheology modifier. It can improve matrix body and reduce excessive flow. Particle size, surface area, moisture content, and trace-metal profile matter because small changes may affect viscosity, coating uniformity, and drug distribution.

Kaolin also creates manufacturing considerations. The raw material must have controlled particle-size distribution and low microbial and elemental impurity levels. Poor dispersion can produce dose nonuniformity or visible defects in the patch.

Sodium carboxymethylcellulose

Sodium carboxymethylcellulose controls water binding and contributes to the hydrocolloid-like properties of the adhesive layer. Degree of substitution, viscosity grade, moisture content, and particle hydration influence coating behavior and finished-patch performance.

A formulation with excessive cellulose hydration may show slower drying, poor liner release, or reduced adhesion during wear. Insufficient hydration can produce brittle films and variable drug release.

Liquid paraffin

Liquid paraffin modifies the hydrophobic phase and can improve flexibility and skin feel. It may reduce brittleness but can also reduce adhesive strength if used at excessive levels. Compatibility with the backing, liner, and adhesive polymer must be tested over the product shelf life.

How does Lidoderm’s excipient strategy control drug release?

Lidocaine release from a patch depends on drug solubility in the adhesive, drug activity, matrix diffusion, skin partitioning, adhesive hydration, and the occlusive properties of the backing.

The principal formulation risks are:

1. Lidocaine crystallization during storage.
2. Inconsistent drug distribution across the coated web.
3. Excessive initial release followed by depletion.
4. Low release caused by excessive drug-polymer binding.
5. Adhesive failure during the labeled 12-hour wear period.
6. Residual drug remaining in the patch after use.

The target is not maximum release. It is controlled delivery that produces adequate local exposure while limiting systemic absorption and skin irritation. The FDA label reports that systemic exposure is proportional to the applied area and duration of use, making patch size, dose loading, and wear time important safety variables.[1]

A developer should characterize:

• Lidocaine solid-state form
• Drug solubility in each excipient phase
• Drug crystallization under accelerated storage
• In vitro release rate
• Skin permeation
• Residual drug after wear
• Adhesion under heat, humidity, motion, and perspiration
• Peel and tack after storage
• Extractables and leachables from backing and liner

What excipient changes create the strongest commercial opportunities?

The most attractive opportunities involve performance improvements that can be demonstrated without changing the fundamental product concept.

Synthetic adhesive replacement

Replacing gelatin with a synthetic polymer system could improve supply consistency, reduce animal-origin concerns, and simplify global registration. Candidate systems include acrylic pressure-sensitive adhesives, polyisobutylene systems, silicone adhesives, and hybrid polymer matrices.

The commercial benefit is strongest where a developer can demonstrate:

• Equivalent or superior adhesion
• Lower skin irritation
• Better storage stability
• Reduced manufacturing variability
• No meaningful change in lidocaine exposure

The regulatory burden rises if the new adhesive changes drug release, local tolerability, or systemic exposure.

Improved skin tolerability

Skin irritation and adhesive residue are common barriers in topical patch use. Opportunities include:

• Lower-irritancy acrylic systems
• Reduced solvent load
• Controlled adhesive hydrophilicity
• Breathable backing films
• Cleaner removal
• Lower edge-lift rates
• Reduced occlusion

A product with materially better tolerability could compete even where generic prices have compressed.

Extended-wear or improved adhesion

Lidoderm is labeled for 12 hours on and 12 hours off. A formulation that remains attached during movement, sweating, or sleep has commercial value even if the dosing interval remains unchanged.

A longer-wear claim would require clinical and regulatory support. A formulation may still be marketed around better real-world adhesion without asserting a new dosing interval, provided promotional claims remain consistent with the approved labeling.

Reduced patch size or lower drug loading

A smaller patch with equivalent clinical performance could reduce material cost, packaging volume, and disposal burden. A lower-loading formulation could also reduce residual drug and improve safety in accidental exposure scenarios.

These changes create a high regulatory risk because the product’s applied dose, surface area, and delivery rate are central to the reference product’s performance.

Heat and humidity stability

Adhesive patches can soften, flow, or lose tack under elevated temperature and humidity. Improved thermal stability supports distribution in warmer climates and reduces product complaints.

Potential approaches include:

• Higher-cohesion acrylic polymers
• Lower-mobility plasticizer systems
• Improved backing films
• Better moisture barriers
• Stabilized release liners
• Tighter control of residual water

What patents protect Lidoderm and its formulation?

Lidoderm’s original patent protection has expired. Historical Orange Book listings for the product included patents covering the lidocaine patch and related product protection, including U.S. Patent Nos. 5,741,510 and 6,096,333. Those patents reached their listed expiration periods during the 2010s, subject to applicable patent-term calculations and regulatory exclusivity.[2]

The commercial protection remaining today is therefore primarily based on:

• Manufacturing know-how
• Adhesive composition controls
• Process parameters
• Supplier qualification
• Product quality history
• Brand recognition
• Distribution access
• State substitution and payer dynamics

A new developer can obtain protection for a redesigned patch through composition, manufacturing, use, or performance claims. The strongest patent candidates usually cover a defined combination of:

• Lidocaine concentration
• Polymer identity and ratio
• Plasticizer or solvent range
• Coating weight
• Residual solvent or water range
• Adhesion window
• Release profile
• Stability against crystallization

Broad claims that merely recite lidocaine in a topical patch face greater validity and infringement risk because of extensive prior art. Narrow claims tied to a measurable performance parameter may provide stronger commercial protection if the parameter is technically meaningful and difficult to design around.

What is the FDA regulatory status of Lidoderm and generic lidocaine patches?

Lidoderm was approved under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act as NDA 020612.[1] Generic lidocaine 5% patches may use the abbreviated new drug application pathway when they demonstrate pharmaceutical equivalence and bioequivalence under FDA requirements.

For a generic patch, the regulatory focus includes:

• Same active ingredient and strength
• Same dosage form
• Same route of administration
• Comparable patch dimensions and drug content
• Quality and performance of the adhesive system
• In vitro release testing
• Adhesion testing
• Residual drug content
• Stability
• Labeling and application instructions

The FDA has issued product-specific guidance for lidocaine topical patch products. Such guidance can address in vitro release, adhesion, and other evidence expected for an abbreviated application.[3]

A materially different patch may require a 505(b)(2) NDA rather than an ANDA. Examples include a different dosing schedule, new indication, substantially different patch design, modified drug delivery, or clinically meaningful changes in local or systemic exposure.

When does Lidoderm lose exclusivity, and what generic entry risks exist?

Lidoderm’s core exclusivity has already expired. Generic entry began years ago, and the U.S. market includes multiple lidocaine 5% patch competitors.

The main risks for a new entrant are no longer basic patent infringement. They are commercial and technical:

Risk	Commercial effect
Low generic reimbursement	Limits price premium
Multiple approved suppliers	Increases substitution pressure
Adhesive failure	Creates recalls and payer losses
Manufacturing scale-up	Causes content-uniformity and coating defects
Raw-material variability	Changes release and adhesion
Brand loyalty among prescribers	Slows conversion
OTC lidocaine products	Expands low-cost substitution options
Label restrictions	Limits differentiated claims

Paragraph IV litigation remains relevant for any newly listed or later-issued formulation patent, but the original Lidoderm estate does not provide a meaningful barrier to standard generic entry. A later entrant would need a new patent position around a differentiated composition or delivery profile.

Which companies compete with Lidoderm?

Competition includes generic manufacturers, branded topical analgesic companies, and manufacturers of alternative lidocaine delivery systems.

Prescription competition

The relevant prescription competitors include generic lidocaine 5% patches marketed by companies such as Amneal, Actavis/Teva, Mylan/Viatris, Sandoz, and other FDA-approved suppliers, depending on current product availability and distributor status.

Over-the-counter competition

OTC lidocaine 4% patches, creams, gels, sprays, and roll-ons compete for lower-acuity pain applications. They benefit from broader consumer access but generally do not provide the same labeled prescription strength as Lidoderm.

Non-lidocaine alternatives

Competing technologies include:

• Capsaicin patches
• Capsaicin creams
• Diclofenac topical products
• Compounded anesthetic creams
• Oral neuropathic pain medicines
• In-office high-dose capsaicin systems

Lidocaine patches retain a practical advantage in localized pain because they deliver treatment to a defined area with limited systemic exposure when used according to labeling.

How strong is the patent estate for a new Lidoderm-like patch?

A new patent estate can be strong if it protects a formulation that produces a measurable and commercially valuable result. The most defensible strategy is layered protection.

Composition claims

These cover specific polymer, solvent, filler, and plasticizer combinations. They are useful for blocking direct copies but can often be designed around.

Manufacturing claims

These may cover:

• Mixing sequence
• Temperature profile
• Deaeration
• Coating weight
• Drying conditions
• Lamination
• Slitting
• Packaging

Manufacturing claims can protect process know-how that is difficult to detect from the finished product, although enforcement may be more difficult.

Method-of-use claims

Potential targets include treatment of localized neuropathic pain, improved application schedules, or defined patient populations. Method-of-use claims may support premium pricing but are vulnerable to label carve-outs and prescribing practices.

Performance claims

Claims based on adhesion, release, crystallization resistance, or reduced skin irritation can create stronger differentiation. They require reliable analytical methods and a product that consistently meets the claimed range.

What licensing and partnering opportunities exist?

The most practical licensing opportunities are in enabling technology rather than the expired Lidoderm brand estate.

Potential assets include:

• Low-irritation pressure-sensitive adhesives
• Synthetic replacements for animal-derived gelatin
• Solvent-free coating processes
• High-temperature-stable patch matrices
• Breathable backings
• Drug-in-adhesive manufacturing platforms
• Analytical methods for lidocaine crystallization
• Contract coating and converting capacity

A specialty pharmaceutical company could license an adhesive platform from a polymer supplier, combine it with lidocaine, and pursue a 505(b)(2) product. A generic company could license a ready-to-scale coating process to reduce development time and manufacturing risk.

Licensing economics depend on whether the technology supports an ANDA, a differentiated 505(b)(2) product, or an improved OTC product. A formulation that requires a new clinical program will generally command a smaller number of potential counterparties but may support greater pricing power.

How does Lidoderm compare with other topical analgesic delivery systems?

Attribute	Lidoderm-type lidocaine 5% patch	OTC lidocaine 4% patch	Capsaicin patch	Topical cream or gel
Primary mechanism	Local sodium-channel blockade	Local sodium-channel blockade	TRPV1-mediated desensitization	Variable by active ingredient
Dose control	High	Moderate	High in clinical settings	Lower
Application precision	High	High	High	Moderate
Adhesive engineering importance	Very high	High	Product-dependent	Low
Systemic exposure	Generally limited	Generally limited	Limited but local reactions common	Variable
Regulatory route	Prescription NDA or ANDA	OTC monograph or approved product	NDA or specialist product	OTC or prescription
Main commercial differentiator	Delivery consistency and tolerability	Access and price	Duration and efficacy	Convenience and flexibility

What manufacturing and intellectual-property barriers matter most?

The key manufacturing barrier is uniform coating of a high-drug-load adhesive over a large web. The process must control:

• Viscosity
• Mixing energy
• Temperature
• Air entrapment
• Coating thickness
• Drying rate
• Lamination pressure
• Slitting accuracy
• Pouch seal integrity

The key intellectual-property barrier is proving that a redesigned patch does not infringe active formulation or manufacturing claims. The practical solution is a freedom-to-operate review focused on polymer combinations, coating processes, patch architecture, and use claims in the target jurisdictions.

Geographic expansion requires separate review of patent status, excipient acceptability, labeling, animal-origin controls, local manufacturing requirements, and reimbursement. The U.S. remains the largest strategic market for a Lidoderm-like product, while Europe and Asia may offer opportunities through national registrations, hospital channels, and local partnerships.

Key Takeaways

• Lidoderm is a lidocaine 5% drug-in-adhesive patch containing gelatin, kaolin, sodium carboxymethylcellulose, propylene glycol, polyacrylic acid, liquid paraffin, and water.
• The core product patents have expired, so standard generic entry is primarily a manufacturing and commercial exercise.
• The best excipient opportunities involve adhesive tolerability, crystallization control, heat stability, clean removal, and reliable 12-hour wear.
• Replacing gelatin with a synthetic polymer system could improve supply and global registration, but it may trigger meaningful equivalence work.
• A standard copy is unlikely to support a price premium. A differentiated patch should pursue composition, performance, or manufacturing claims.
• ANDA development is appropriate for a materially equivalent product. A 505(b)(2) NDA is more suitable for a new delivery profile, dosing regimen, indication, or substantially changed formulation.
• The strongest licensing targets are adhesive platforms, coating technology, breathable backings, and analytical methods rather than the expired Lidoderm brand estate.
• Generic launch risk is high from price competition, multiple suppliers, OTC alternatives, and payer substitution.

FAQs About Lidoderm Excipient and Commercial Strategy

Can gelatin be removed from a generic Lidoderm formulation?

Yes. A developer can use a synthetic or semisynthetic adhesive system, but the replacement must preserve drug release, adhesion, stability, and skin tolerability. The regulatory burden depends on the degree of formulation and performance difference.

Is propylene glycol essential to Lidoderm performance?

No. Propylene glycol is an important solvent and plasticizer in the labeled formulation, but alternative solvents or polymer systems may be possible. Any replacement can change lidocaine solubility, crystallization, permeation, and skin irritation.

Can a company patent a smaller lidocaine patch?

Yes, if the smaller patch has a novel composition, delivery profile, manufacturing process, or clinically relevant performance. Size alone may not provide strong patent protection because patch dimensions are readily modified.

Does a lidocaine 5% patch require biosimilar development?

No. Lidocaine is a small-molecule active ingredient. A lidocaine patch is developed through an ANDA or NDA pathway, not the biosimilar pathway used for biological products.

What is the most valuable improvement over Lidoderm?

The strongest commercial candidates are patches with better adhesion and lower irritation while maintaining controlled lidocaine release. Improvements that reduce edge lift, residue, and skin reaction can support differentiation in an otherwise price-driven market.

References

1. U.S. Food and Drug Administration. (2023). Lidoderm (lidocaine patch 5%) prescribing information. Endo Pharmaceuticals Inc.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2024). Product-specific guidances for generic drug development. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/product-specific-guidances-generic-drug-development